AU2017329549B2 - Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof - Google Patents

Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof Download PDF

Info

Publication number
AU2017329549B2
AU2017329549B2 AU2017329549A AU2017329549A AU2017329549B2 AU 2017329549 B2 AU2017329549 B2 AU 2017329549B2 AU 2017329549 A AU2017329549 A AU 2017329549A AU 2017329549 A AU2017329549 A AU 2017329549A AU 2017329549 B2 AU2017329549 B2 AU 2017329549B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutical composition
optionally
ranges
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017329549A
Other languages
English (en)
Other versions
AU2017329549A1 (en
Inventor
Xiaocui GUO
Zhenhua Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61689352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017329549(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2017329549A1 publication Critical patent/AU2017329549A1/en
Application granted granted Critical
Publication of AU2017329549B2 publication Critical patent/AU2017329549B2/en
Assigned to KBP BIOSCIENCES PTE. LTD. reassignment KBP BIOSCIENCES PTE. LTD. Request for Assignment Assignors: KBP BIOSCIENCES CO., LTD.
Assigned to NOVO NORDISK A/S reassignment NOVO NORDISK A/S Request for Assignment Assignors: KBP BIOSCIENCES PTE. LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2017329549A 2016-09-24 2017-09-22 Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof Active AU2017329549B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610849142 2016-09-24
CN201610849142.4 2016-09-24
PCT/CN2017/102969 WO2018054357A1 (zh) 2016-09-24 2017-09-22 含盐皮质激素受体拮抗剂的药物组合物及其用途

Publications (2)

Publication Number Publication Date
AU2017329549A1 AU2017329549A1 (en) 2019-04-11
AU2017329549B2 true AU2017329549B2 (en) 2020-05-14

Family

ID=61689352

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017329549A Active AU2017329549B2 (en) 2016-09-24 2017-09-22 Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof

Country Status (29)

Country Link
US (2) US11806344B2 (enExample)
EP (1) EP3517113A4 (enExample)
JP (2) JP7090599B2 (enExample)
KR (1) KR102226516B1 (enExample)
CN (1) CN109069502B (enExample)
AU (1) AU2017329549B2 (enExample)
BR (1) BR112019005214A2 (enExample)
CA (1) CA3037588C (enExample)
CL (1) CL2019000753A1 (enExample)
CO (1) CO2019003808A2 (enExample)
CR (2) CR20240015A (enExample)
CU (1) CU24569B1 (enExample)
DO (1) DOP2019000072A (enExample)
EA (1) EA201990668A1 (enExample)
EC (1) ECSP19027578A (enExample)
IL (1) IL265560B (enExample)
MA (1) MA45202B1 (enExample)
MX (1) MX391602B (enExample)
MY (1) MY195054A (enExample)
NZ (1) NZ751901A (enExample)
PE (1) PE20190608A1 (enExample)
PH (1) PH12019500516A1 (enExample)
RU (2) RU2725153C1 (enExample)
SG (1) SG10201912389WA (enExample)
TN (1) TN2019000063A1 (enExample)
TW (2) TWI780488B (enExample)
UA (1) UA123464C2 (enExample)
WO (1) WO2018054357A1 (enExample)
ZA (1) ZA201901740B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24569B1 (es) 2016-09-24 2022-01-13 Kbp Biosciences Co Ltd Composición farmacéutica como antagonista del receptor de mineralocorticoides
CN113425683B (zh) * 2021-08-19 2022-09-20 谢彩华 一种三氮脒缓释注射剂及其制备方法
CN116492336B (zh) * 2023-04-04 2024-07-05 迪沙药业集团有限公司 一种坎地沙坦酯药物组合物
CN120168468B (zh) * 2025-03-05 2025-10-17 苏州天马医药集团天吉生物制药有限公司 一种非奈利酮制剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946279B2 (en) * 2010-08-18 2015-02-03 Kbp Biosciences Co., Ltd. Fused ring compound for use as mineralocorticoid receptor antagonist

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700395A2 (en) * 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
TWI431010B (zh) * 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
JP5846647B2 (ja) * 2010-02-25 2016-01-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アピキサバン製剤
HUE034890T2 (hu) * 2010-10-29 2018-03-28 Algiax Pharmaceuticals Gmbh Malononitrilaminok alkalmazása neuropathiás fájdalomban
AU2013362400B2 (en) 2012-12-22 2016-07-28 Novo Nordisk A/S Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor
CU24569B1 (es) 2016-09-24 2022-01-13 Kbp Biosciences Co Ltd Composición farmacéutica como antagonista del receptor de mineralocorticoides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946279B2 (en) * 2010-08-18 2015-02-03 Kbp Biosciences Co., Ltd. Fused ring compound for use as mineralocorticoid receptor antagonist

Also Published As

Publication number Publication date
TN2019000063A1 (en) 2020-07-15
MY195054A (en) 2023-01-05
MX2019003339A (es) 2019-06-03
DOP2019000072A (es) 2019-06-16
JP2019532939A (ja) 2019-11-14
CR20190203A (es) 2019-06-26
CA3037588C (en) 2022-07-12
RU2725153C1 (ru) 2020-06-30
ECSP19027578A (es) 2019-07-31
TW202100156A (zh) 2021-01-01
TW201813645A (zh) 2018-04-16
CO2019003808A2 (es) 2019-04-30
CR20240015A (es) 2024-04-05
RU2750667C2 (ru) 2021-06-30
CN109069502A (zh) 2018-12-21
TWI780488B (zh) 2022-10-11
RU2020120876A3 (enExample) 2020-12-28
KR102226516B1 (ko) 2021-03-12
CN109069502B (zh) 2021-08-06
US11806344B2 (en) 2023-11-07
IL265560B (en) 2022-07-01
MA45202A1 (fr) 2020-11-30
US20190201390A1 (en) 2019-07-04
CL2019000753A1 (es) 2019-07-19
PH12019500516A1 (en) 2020-02-24
BR112019005214A2 (pt) 2019-06-11
CA3037588A1 (en) 2018-03-29
JP7090599B2 (ja) 2022-06-24
AU2017329549A1 (en) 2019-04-11
TWI715806B (zh) 2021-01-11
UA123464C2 (uk) 2021-04-07
CU24569B1 (es) 2022-01-13
US20240016796A1 (en) 2024-01-18
KR20190057323A (ko) 2019-05-28
PE20190608A1 (es) 2019-04-23
EP3517113A1 (en) 2019-07-31
MX391602B (es) 2025-03-21
EP3517113A4 (en) 2020-07-08
NZ751901A (en) 2021-07-30
RU2020120876A (ru) 2020-08-26
MA45202B1 (fr) 2022-04-29
HK1258622A1 (zh) 2019-11-15
IL265560A (en) 2019-05-30
JP2022037044A (ja) 2022-03-08
EA201990668A1 (ru) 2019-10-31
ZA201901740B (en) 2019-10-30
SG10201912389WA (en) 2020-02-27
WO2018054357A1 (zh) 2018-03-29
CU20190023A7 (es) 2019-11-04

Similar Documents

Publication Publication Date Title
US20240016796A1 (en) Pharmaceutical Composition Comprising Mineralocorticoid Receptor Antagonist and Use Thereof
JP4891774B2 (ja) ナノ粒子のメロキシカム製剤
EP0942721B1 (en) Liquid composition comprising an hiv protease inhibitor and a c12-c18 fatty acid
JP2006528176A (ja) 新規シルデナフィル遊離塩基組成物
WO2002049646A1 (en) Therapeutic combination of amlodipine and benazepril/benazeprilat
KR20150004921A (ko) 1,1-디메틸에틸 [(1s)-1-｛[(2s,4r)-4-(7-클로로-4메톡시이소퀴놀린-1-일옥시)-2-(｛(1r,2s)-1-[(시클로프로필술포닐)카르바모일]-2-에테닐시클로프로필｝카르바모일)피롤리딘-1-일]카르보닐｝-2,2-디메틸프로필]카르바메이트의 가용화된 캡슐 제제
CN103249415B (zh) 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
JP2010502710A (ja) Ｃｇｒｐ拮抗薬の経口投与のための液体医薬製剤
HK40004404A (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
US20220347121A1 (en) Methods of preparing compositions containing thymoquinone
EA041410B1 (ru) Применение антагониста минералокортикоидных рецепторов для лечения хронической болезни почек и способ лечения хронической болезни почек
HK1258622B (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
US20250319070A1 (en) Losartan liquid formulations and methods of use
WO2000037083A1 (en) Oral antiestrogen pharmaceutical composition
EP4093381A1 (en) Bilayer tablet comprising telmisartan and amlodipine
HK1022441A1 (en) Liquid composition comprising an hiv protease inhibitor and a c12-c18 fatty acid
HK1022441B (en) Liquid composition comprising an hiv protease inhibitor and a c12-c18 fatty acid
MX2013015100A (es) Combinacion sinergica para el tratamiento de hipertension.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: KBP BIOSCIENCES PTE. LTD.

Free format text: FORMER OWNER(S): KBP BIOSCIENCES CO., LTD.

PC Assignment registered

Owner name: NOVO NORDISK A/S

Free format text: FORMER OWNER(S): KBP BIOSCIENCES PTE. LTD.